A rotation study through the main therapeutic classes of antihypertensive in patients with polycystic kidney disease and hypertension

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN57653760

Enrollment

Registered

2003-09-12

Start date

2000-02-24

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular: Hypertension Circulatory System Hypertension

Interventions

Following a 2-week placebo run-in period, patients eligible to enter this crossover, double-blind study will receive in a randomised order, daily, and for a six week period: 1. Amlodipine (5 mg) 2. D

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 40 outpatients aged 18 - 65 years.

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Primary

Measure	Time frame
Not provided at time of registration	—

Secondary

Measure	Time frame
Not provided at time of registration	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026